aminocaproic acid has been researched along with Coronary Disease in 5 studies
Aminocaproic Acid: An antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties.
6-aminohexanoic acid : An epsilon-amino acid comprising hexanoic acid carrying an amino substituent at position C-6. Used to control postoperative bleeding, and to treat overdose effects of the thrombolytic agents streptokinase and tissue plasminogen activator.
Coronary Disease: An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sixty patients were randomized in a double-blind fashion to receive epsilon-aminocaproic acid, aprotinin, or saline (placebo) in similar dosing regimens (loading dose, pump prime, and infusion)." | 2.71 | Antifibrinolytic therapy during cardiopulmonary bypass reduces proinflammatory cytokine levels: a randomized, double-blind, placebo-controlled study of epsilon-aminocaproic acid and aprotinin. ( Brouse, CF; Chi, L; Dimaio, JM; Greilich, PE; Jessen, ME; Whitten, CW, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (40.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Stassano, P | 1 |
| Musumeci, A | 1 |
| Santise, G | 1 |
| Gagliardi, C | 1 |
| Montalto, A | 1 |
| Spampinato, N | 1 |
| Greilich, PE | 1 |
| Brouse, CF | 1 |
| Whitten, CW | 1 |
| Chi, L | 1 |
| Dimaio, JM | 1 |
| Jessen, ME | 1 |
| Levati, A | 1 |
| Minella, C | 1 |
| Farina, ML | 1 |
| D'Angelo, V | 1 |
| Ray, MJ | 1 |
| Hales, MM | 1 |
| Brown, L | 1 |
| O'Brien, MF | 1 |
| Stafford, EG | 1 |
| Cresanta, DA | 1 |
| Pacifico, AD | 1 |
| Blackstone, EH | 1 |
2 trials available for aminocaproic acid and Coronary Disease
| Article | Year |
|---|---|
Antifibrinolytic therapy during cardiopulmonary bypass reduces proinflammatory cytokine levels: a randomized, double-blind, placebo-controlled study of epsilon-aminocaproic acid and aprotinin.
Topics: Aged; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Cardiopulmonary Bypass; Coronary Artery | 2003 |
Postoperatively administered aprotinin or epsilon aminocaproic acid after cardiopulmonary bypass has limited benefit.
Topics: Aged; Aminocaproic Acid; Aprotinin; Cardiopulmonary Bypass; Coronary Artery Bypass; Coronary Disease | 2001 |
3 other studies available for aminocaproic acid and Coronary Disease
| Article | Year |
|---|---|
Can epsilon-aminocaproic acid balance the off-pump bleeding advantage?
Topics: Aged; Aminocaproic Acid; Assisted Circulation; Chi-Square Distribution; Coronary Artery Bypass; Coro | 2003 |
Potential hazards of antifibrinolytic treatment in subarachnoid haemorrhage.
Topics: Aminocaproates; Aminocaproic Acid; Coronary Disease; Humans; Male; Middle Aged; Pulmonary Embolism; | 1980 |
The use of epsilon-aminocaproic acid to reduce bleeding following coronary artery revascularization.
Topics: Aminocaproates; Aminocaproic Acid; Coronary Disease; Hemorrhage; Humans; Myocardial Revascularizatio | 1977 |